The drug, called carbetocin and made by Ferring Pharmaceuticals,
could prove a useful alternative to oxytocin - currently recommended
as the first-choice medicine for preventing excessive bleeding after
childbirth.
Oxytocin needs to be transported and stored at between 2 and 8
degrees Celsius, making it tricky to use in many poor countries
where infrastructure and power supply can be limited.
This means many women don't get a life-saving drug during
childbirth, the WHO researchers said. Other women might get it only
to find it has lost its efficacy due to heat exposure.
The study, published in the New England Journal of Medicine on
Wednesday, found that carbetocin - a heat-stable drug - is as safe
and effective as oxytocin in preventing postpartum bleeding.

The drug is robust and stable enough to be transported and used in
hot climates where cold storage can be a problem. It doesn't require
refrigeration and retains efficacy for at least three years even at
30 degrees Celsius (86°F) and 75 percent humidity.
Tedros Adhanom Ghebreyesus, the WHO's director-general, said the
finding was "a truly encouraging new development" that could
"revolutionize our ability to keep mothers and babies alive".
[to top of second column] |

Around 70,000 women die each year worldwide due to post-partum
hemorrhage. Their deaths also increase the risk that their newborns
will also die within a month.
The trial looked at 30,000 women who gave birth vaginally in 10
countries: Argentina, Egypt, India, Kenya, Nigeria, Singapore, South
Africa, Thailand, Uganda and Britain.
Each woman was randomized to get either a single injection of
heat-stable carbetocin or oxytocin immediately following the birth
of her baby. The results showed both drugs were equally effective in
preventing excessive bleeding after childbirth.
The next step will be to submit carbetocin for regulatory review and
approval by countries wishing to use it, the WHO said, after which
it will be considered for potential addition to the WHO's list of
recommended drugs for post-partum bleeding.
(Editing by Louise Heavens)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |